Evaluating a new screening method for esophageal and gastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the feasibility and effectiveness of a risk-based sequential screening approach for esophageal and gastric cancers in a high-risk region of northern China. Participants aged 50 to 69 from selected villages in Xun County will be randomly assigned to either a sequential screening group, where only high-risk individuals receive endoscopic screening, or a universal screening group, where all participants undergo screening. The goal is to improve detection rates of upper gastrointestinal malignant lesions while optimizing resource use. The study will involve approximately 21,000 participants and aims to demonstrate the health-economic value of this targeted screening strategy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Permanent residency in the target villages in Xun County, Henan Province, China;
* Aged 50 to 69 at the enrollment;
* Voluntarily participate in this study and provide informed consent.

Exclusion Criteria:

* Had a history of endoscopic examination within 5 years prior to the initial interview;
* Had a history of cancer;
* Had a history of mental disorder;
* Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV);
* Had severe cardiovascular and cerebrovascular diseases;
* Had severe respiratory disease, dyspnea, or asthmaticus status;
* Had retropharyngeal abscess, severe spinal deformity, or aortic aneurysm;
* With physical debility unable to tolerate endoscopic examination, or with difficulty in achieving sedation and self-control;
* In the acute phase of corrosive inflammation of the upper gastrointestinal tract, or with suspected perforation of the upper gastrointestinal tract;
* Had massive ascites, severe abdominal distension, or severe esophageal varices;
* Pregnancy;
* Had severe history of allergies;
* Had propensity for bleeding (coagulopathy);
* Others unable to tolerate the clinical examinations involved in this study.

Where it's running

• Department of genetics, Peking University Cancer Hospital & Institute
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Zhonghu He
• Email: zhonghuhe@bjcancer.org
• Phone: 010-88196702

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

• Prehabilitation before high-risk cancer surgery

  This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.

  Recruiting Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07638410

• Molecular comparison of primary gastroesophageal cancers and their brain metastases

  This project will test whether key biomarkers (HER2, MSI, PD-L1, CLDN18.2) match between primary gastroesophageal tumors and their matched brain metastases using archived tissue.

  Recruiting Blokhin's Russian Cancer Research Center · Moscow · NCT07464470

• Sonesitatug vedotin plus capecitabine, with or without rilvegostomig, for CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma

  This trial will test whether adding sonesitatug vedotin to capecitabine, with or without rilvegostomig, helps people with untreated CLDN18.2-positive, HER2-negative advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma.

  Recruiting at 158 sites Phase 3 AstraZeneca · Birmingham, Alabama and 313 other locations · NCT07431281

• PET imaging that targets CLDN18.2 to find stomach, pancreatic, bile-duct, and esophageal cancers

  This project will try a CLDN18.2-targeted PET scan in adults with suspected or confirmed gastric, pancreatic, bile-duct, or esophageal cancer (and some healthy volunteers) to see if it can show CLDN18.2-positive tumors.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07301814

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.